Arrayit Corporation Logo

Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.  - Powerful Science for Life™

Corporate - Media & Press - Press Release - New Zealand Patent

Arrayit Awarded Multi-Patient Genotyping Patent in New Zealand.

Sunnyvale, CA, June 7, 2006 – On May 11th, Arrayit was awarded a patent for its multi-patient genotyping technology from the Intellectual Property Office of New Zealand. Neville Harris, Commissioner of Patents, Trade Marks and Designs, signed the letters patent number 523560 granting Arrayit patent protection on its invention entitled “Microarray Method of Genotyping Multiple Patients at Multiple Loci”.  In 2005, the United States Patent and Trademark office issued U.S. patent 6,913,879 on the same invention, followed by the nation of Singapore (94899), granting the company patent protection for its methods of genotyping many patients at once.  In a preferred embodiment, patient samples are amplified by the polymerase chain reaction, configured into microarrays, hybridized with fluorescent oligonucleotides, and genotyped by reading the microarray signals.  Because the patient DNA forms the microarray, as many as 100,000 patients can be genotyped in a single hybridization reaction.  Multi-patient technology greatly reduces the cost of patient genotyping compared to traditional “single patient” techniques, and the company is currently offering multi-patient genotyping products and services via its Diagnostics Division.

Company President Rene’ Schena shared her thoughts on TeleChem’s New Zealand patent number 523560.  “We were very pleased to hear of the issuance of our New Zealand patent.  Our exciting “patient on the chip” methods are gaining widespread protection worldwide by virtue of issued patents in the United States, Singapore and New Zealand.  We have also recently received very positive feedback from the European office.  This places our company in a sound position to participate in the genetic screening, testing and diagnostics markets worldwide.  We thank the New Zealand patent office for their diligence in examining and approving our application.”

The issuance of TeleChem’s New Zealand Patent has been featured widely by the international news media and by on-line news providers such as Pharmacy Choice and NewsRx™.

Arrayit patents

About Arrayit
TeleChem International is a privately owned high-tech company located in the heart of California’s Silicon Valley.  Our products and services are provided by three corporate divisions: ArrayIt® Life Sciences Division, Chemicals Division, and a Diagnostics Division. The ArrayIt® Life Sciences Division offers a complete microarray technology platform that empowers >10,000 laboratories to use microarrays for human genome exploration, basic research, drug discovery, and myriad life sciences applications.  Nearly every major research institution uses our patented microarray manufacturing technology (U.S. 6,101,946) and supporting products and services.  The Chemicals Division provides import and export services and government contract manufacturing in the area of industrial chemicals for plastics, fire control, water treatment, agriculture, industrial and institutional compounding, and green energy. The Diagnostics Division holds key patents in the United States (6,913,879), Singapore (94899), New Zealand (523560), and other countries for its revolutionary “multi-patient” genotyping technology, which allows as many as 100,000 patients to be tested on a single microarray. Arrayit Diagnostics enables genotyping and disease diagnostics by providing testing kits, services, and technology transfer opportunities for disease screening and testing organizations.

Media Contact
Arrayit Corporation
Telephone: 408-744-1331
Email: investorrelations@arrayit.com
Web: www.arrayit.com
 

 

Copyright 1993-2017 Arrayit Corporation. All rights reserved.